CDC Advisory Committee recommends first single-shot COVID-19 vaccine for US adults

The US Centres for Disease Control and Prevention’s (CDC) Advisory Committee on Immunisation Practices (ACIP) has recommended the first single-shot COVID-19 vaccine – developed by the Janssen Pharmaceutical Companies of Johnson & Johnson – for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the US FDA.

ACIP is a body of independent health experts that advises the CDC on the types of populations and circumstances for which vaccines should be used.

The ACIP recommendation will be forwarded to the Director of the CDC and the U.S. Department of Health and Human Services (HHS) for review and adoption.

Johnson & Johnson’s single-shot COVID-19 vaccine received EUA from the FDA on February 27, 2021. The terms of the EUA allow use of the vaccine while more data are gathered. The Company plans to file for a Biologics License Application (BLA) with the FDA later this year.

“This recommendation follows the FDA’s decision to grant an Emergency Use Authorization for our single-shot vaccine, which has the potential to play a pivotal role in helping to end the COVID-19 pandemic,” said Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news